# Adial Pharmaceuticals (ADIL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ADIL
## Company Profile
- Ticker: ADIL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 6.66 USD
- Market cap: 5058945.56 USD
- Last updated: 2026-09-03
## Business Overview
Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.
## Why The Stock Is Moving

As of Sep 3, 2026, ADIL closed up 5.38% at $6.66. No new same-company headline was identified in the current news window.

## Geographic Base

Adial is headquartered in the United States and listed on NASDAQ, with a small-cap specialty-biopharma profile. It sits in addiction medicine rather than mainstream oncology or immunology.

## Business Model

The business depends on clinical progress, regulatory strategy, and the ability to show that its candidate can create a meaningful treatment option in addiction care. Investors usually watch proof-of-concept data, safety, and commercialization potential.

## Landscape Position

Adial occupies a niche addiction-medicine position within biotech. The stock is catalyst-sensitive because the company is still trying to prove a focused therapeutic thesis in a difficult indication.

## Future Catalysts

- Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive. The company still needs a stronger human signal.

## Recent News
- 2025-06-11 08:00 EST — [Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-advances-toward-phase-3-development-for-ad04) — Source: Adial Pharmaceuticals
- 2025-05-15 08:30 EST — [Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-update) — Source: Adial Pharmaceuticals
- 2025-05-13 08:30 EST — [Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-receives-milestone-payment-from-adovate-following-initiation-of-phase-1-study) — Source: Adial Pharmaceuticals
- 2025-05-08 08:30 EST — [Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration) — Source: Adial Pharmaceuticals
- 2025-05-02 11:48 EST — [Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-a-warrant-inducement-transaction-for-2-75-million-in-gross-proceeds) — Source: Adial Pharmaceuticals